Synovial Sarcoma - Epidemiology Forecast – 2030

Synovial Sarcoma - Epidemiology Forecast – 2030

  • January 2021 •
  • 101 pages •
  • Report ID: 6025293 •
  • Format: PDF
‘Synovial Sarcoma (SyS) – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of and historical and forecasted epidemiology of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Synovial Sarcoma Disease Understanding
Synovial sarcoma (SyS), which may also be called malignant synovioma, is cancer that can originate from different types of soft tissue, such as muscle or ligaments. It is often found in the arm, leg, or foot and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen.
On a pathology report, SyS may be classified into different subtypes depending on what it looks like under the microscope or what specific gene mutation is involved. SyS is a high-grade tumor. It spreads to distant sites in up to 50% of cases. The symptoms caused by SyS depend on where the tumor forms. It is often first noticed as a painless lump. If it is near a nerve, it might cause pain or numbness as it grows.

Synovial Sarcoma Epidemiology
The SyS epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings
The total incident cases of synovial sarcoma patients are increasing in the 7MM during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted synovial sarcoma symptoms epidemiology segmented as the incidence of synovial sarcoma, gender-specific cases of synovial sarcoma, age-specific cases of synovial sarcoma, location-specific cases of synovial sarcoma, and stage-specific cases of synovial sarcoma. The report includes the incident scenario of synovial sarcoma symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Synovial Sarcoma Epidemiology
The epidemiology segment also provides the synovial sarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed incident cases of synovial sarcoma associated in 7MM countries were 1,610 in 2020.
• As per the estimates, the United States has the largest incident population of synovial sarcoma.
• Among the EU5 countries, Germany had the highest incident cases of synovial sarcoma, followed by France. On the other hand, Spain had the lowest prevalent cases with 116 cases in 2020.

Scope of the Report
• The synovial sarcoma report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The synovial sarcoma epidemiology report and model provide an overview of synovial sarcoma’s risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into synovial sarcoma’s historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of synovial sarcoma.
• The report provides the synovial sarcoma epidemiology segmentation by incident cases of Synovial Sarcoma in the 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by gender-specific prevalent cases of synovial sarcoma in 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by age-specific prevalent cases of synovial sarcoma in 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by location-specific cases of synovial sarcoma in 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by stage-specific cases of synovial sarcoma in 7MM.

Report Highlights

• 10-year Forecast of Synovial Sarcoma epidemiology
• 7MM Coverage
• Incident Cases of Synovial Sarcoma
• Incident Cases according to segmentation: Gender-specific cases of Synovial Sarcoma
• Incident Cases according to segmentation: Age-specific cases of Synovial Sarcoma
• Incident Cases according to segmentation: Location-specific cases of Synovial Sarcoma
• Incident Cases according to segmentation: Stage-specific cases of Synovial Sarcoma

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population about synovial sarcoma?
• What are the key findings of the synovial sarcoma epidemiology across 7MM, and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of synovial sarcoma patients across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow by 7MM during the study period (2018–2030)?
• What are the disease risk, burdens, and unmet needs of synovial sarcoma?
• What are the currently available treatments for synovial sarcoma?

Reasons to buy
The synovial sarcoma epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global synovial sarcoma market.
• Quantify patient populations in the global synovial sarcoma market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for synovial sarcoma therapeutics in each of the markets covered.
• Understand the magnitude of the insomnia population by its total incident cases.
• Understand the magnitude of the synovial sarcoma population by its gender-specific cases.
• Understand the magnitude of the synovial sarcoma population by its age-specific cases.
• Understand the magnitude of the synovial sarcoma population by its location-specific cases.
• Understand the magnitude of the synovial sarcoma population by its stage-specific cases.
• The synovial sarcoma epidemiology report and model were written and developed by masters and Ph.D. level epidemiologists.
• The synovial sarcoma epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030
As reported in a recent report by Nedra et al. (2019) in the article titled “Incidence and prevalence of synovial sarcoma in the US: An analysis using SEER*Stat,” the age-adjusted incidence rate of synovial sarcoma was 0.177/100,000 in 2018. According to this report, there were about 580 cases of synovial sarcoma in 2018. The article also reports that SyS is more frequently manifested in patients aged 20–49 years, with the highest occurrence of new cases in patients between 45 and 49 years (incidence rate 0.26/100,000). They analyzed data from 18 registries of the Surveillance, Epidemiology, and End Results (SEER), and incidence rates were projected based on data from 2011 to 2015. These incidence projected by NCI and the above-mentioned article, along with other reports, were used to construct the forecasting model for the present report. The prevalence rate of SyS across all ages was 0.65/100,000 (estimated 2129 prevalent cases) as of January 1, 2018. The disease burden of SyS is generally extrapolated from overall soft tissue sarcoma (STS), with SyS accounting for 4.5% of all STS (587 cases estimated in 2018 in the US).
In another report titled “Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with a minimum follow-up of 10 years for survivors” written by Krieg et al. (2011), it was estimated that synovial sarcoma most frequently affects extremities in which it occurs most frequently in the lower (62%) and upper (21%) extremities. On a similar line, another article by Sultan et al. (2009) also noted that almost 70% of synovial sarcoma cases are located in extremities. Other sites that were affected most were the trunk, head, neck, lung, and pleura.